Search Results
Your search for ,Per matches 4038 pages
Showing 1851 - 1900Different Doses of Adjuvant Ipilimumab vs High-Dose Interferon Alfa-2b in Patients With Resected High-Risk Melanoma
As reported in the Journal of Clinical Oncology by Tarhini et al, the phase III Intergroup E1609 trial has shown an overall survival advantage with adjuvant ipilimumab at 3 mg/kg—but not at 10 mg/kg—vs high-dose interferon alfa-2b in patients with resected high-risk cutaneous melanoma. The...
Selected Abstracts on New Therapies for Newly Diagnosed Multiple Myeloma
To complement The ASCO Post’s comprehensive coverage of the 2019 American Society of Hematology (ASH) Annual Meeting & Exposition, here are several abstracts selected from the meeting proceedings focusing on novel therapeutic regimens including the monoclonal antibody daratumumab in combination ...
ADMIRAL Trial: Gilteritinib Improves Overall Survival in Relapsed or Refractory FLT3-Mutated AML
As reported in The New England Journal of Medicine by Alexander E. Perl, MD, of Abramson Cancer Center, University of Pennsylvania, and colleagues, the phase III ADMIRAL trial showed improved overall survival with the oral FMS-like tyrosine kinase 3 (FLT3) inhibitor gilteritinib vs salvage...
Entrectinib in Advanced or Metastatic NTRK Fusion–Positive Solid Tumors
As reported in The Lancet Oncology by George D. Demetri, MD, and colleagues, integrated analysis of three phase I/II trials has shown high levels of activity of the tropomyosin receptor kinase (TRK) inhibitor entrectinib in advanced NTRK fusion–positive solid tumors. This analysis supported the...
Is There an Association Between Powder Use and Risk of Ovarian Cancer?
As reported in JAMA by O’Brien et al, pooled data from four large U.S.-based prospective cohorts suggest the lack of a significant association between the use of powder in the genital area and an increased risk of ovarian cancer. The investigators noted that the analysis may have not been...
Prevalence of Alcohol Use Among Patients With Cancer and Survivors
New research published by Nina N. Sanford, MD, and colleagues in JNCCN—Journal of the National Comprehensive Cancer Network has found most cancer survivors reported that they are current alcohol drinkers, with a subset of those survivors self-reporting excessive drinking behaviors. “We recommend...
Largest Single-Year Drop in Cancer Mortality Reported in ‘Cancer Statistics, 2020’
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017—the largest single-year drop in cancer mortality ever reported. These findings were reported in “Cancer Statistics, 2020,” the latest edition of the American Cancer Society’s annual report on cancer...
Physical Activity at Recommended Levels May Lower Risk of Multiple Cancers
A pooled analysis of nine prospective studies involving more than 750,000 adults has found that recommended amounts of leisure-time physical activity were linked to a lower risk for seven cancers, with several cancer types having a dose/response relationship. These findings were published by...
JAVELIN Bladder 100 Study of Avelumab for Urothelial Cancer Meets Primary Endpoint
The phase III JAVELIN Bladder 100 trial met its primary endpoint of overall survival at the planned interim analysis. In this study, patients with previously untreated locally advanced or metastatic urothelial carcinoma whose disease did not progress on induction chemotherapy and who were randomly...
Saliva Test May Play A Role in the Early Detection of HPV-Related Oropharyngeal Cancer
A report by Wang et al in The Journal of Molecular Diagnostics described the use of acoustofluidics, a noninvasive method that analyzes saliva for the presence of human papillomavirus type 16 (HPV-16), the pathogenic strain of the disease associated with oropharyngeal cancers. This novel technique...
Pembrolizumab vs Cetuximab Plus Chemotherapy in Recurrent or Metastatic Head/Neck Squamous Cell Cancer
As reported in The Lancet by Barbara Burtness, MD, of the Department of Medicine, Yale University School of Medicine, and colleagues, the phase III KEYNOTE-048 trial has shown improved overall survival with first-line pembrolizumab plus chemotherapy vs cetuximab plus chemotherapy among patients...
FDA Pipeline: Priority Reviews in SCLC, Bladder Cancer, Colorectal Cancer
Recently, the U.S. Food and Drug Administration (FDA) granted Priority Reviews for treatments in extensive-stage small cell lung cancer (SCLC), non–muscle invasive bladder cancer, and BRAF V600E–mutant colorectal cancer. The Agency also recently issued multiple Breakthrough Therapy designations and ...
Incidence of Squamous Cell Carcinoma of the Anus Has ‘Increased Dramatically’ in Older Women and Young Black Men
“Squamous cell carcinoma of the anus incidence has increased dramatically in elderly women and young black men,” according to a study of recent trends in incidence and mortality. “Advanced-stage [anal squamous cell carcinoma] incidence tripled with a prominent rise in … mortality,” researchers...
How Effective Is Supplemental MRI Screening for Women With Extremely Dense Breasts?
In the Dutch DENSE study reported in The New England Journal of Medicine, Bakker et al found that supplemental magnetic resonance imaging (MRI) in women with extremely dense breast tissue and normal results on screening mammography was associated with the diagnosis of significantly fewer interval...
Phase Ib/II Studies Explore Next-Generation BCMA-Targeted CAR T-Cell Therapies in Multiple Myeloma
In patients with relapsed or refractory multiple myeloma, two novel dual-target chimeric antigen receptor (CAR) T-cell strategies are yielding early and durable responses, with seemingly less cytokine-release syndrome and neurotoxicity than first-generation CAR T-cell products, according to the...
ESMO Immuno-Oncology 2019: Safety Analysis Results for First-Line Durvalumab Plus Platinum/Etoposide in Extensive-Stage SCLC
Few grade 3 or higher immune-related adverse events were observed in patients treated with first-line durvalumab plus platinum/etoposide for extensive-stage small cell lung cancer (SCLC), according to findings from the safety analysis of the phase III CASPIAN study presented by Özgüroğlu et al at...
Rising Cost and Use of Oral Anticancer Drugs and Increased Medicare Part D Spending
In a study reported in a research letter in JAMA Oncology, Emily Stamell Ruiz, MD, MPH, and colleagues found that rising drug costs and use accounted for 56% and 44%, respectively, of increased Medicare Part D spending on oral anticancer drugs between 2013 and 2017. Study Details The analysis...
Does Second-Line Pembrolizumab in Patients With Advanced Hepatocellular Carcinoma Previously Treated With Sorafenib Confer a Survival Benefit?
As reported in the Journal of Clinical Oncology by Richard S. Finn, MD, and colleagues, the phase III KEYNOTE-240 trial has shown no statistically significant progression-free or overall survival benefit with pembrolizumab vs placebo in patients with advanced hepatocellular carcinoma who were...
How to Give Effective Presentation Feedback
Giving an effective scientific presentation, like all public speaking, is an acquired skill that takes practice to perfect. When delivered successfully, an oral presentation can be an invaluable opportunity to showcase your latest research results among your colleagues and peers. It can also...
Veliparib/Chemotherapy Combination Active in HER2-Negative BRCA-Positive Advanced Breast Cancer
The addition of the poly (ADP-ribose) polymerase (PARP) inhibitor veliparib to carboplatin/paclitaxel chemotherapy significantly improved progression-free survival in patients with advanced HER2-negative breast cancer and germline BRCA mutation compared with placebo plus chemotherapy, according to...
ESMO Immuno-Oncology 2019: Sitravatinib/Tislelizumab Shows Antitumor Activity in Ovarian Cancer
Results from a phase Ib study reported at the European Society for Medical Oncology (ESMO) Immuno-Oncology Congress 2019 showed manageable safety and encouraging antitumor activity in patients with advanced ovarian cancer treated with the novel combination of sitravatinib and tislelizumab. These...
SABCS 2019: Oral vs Intravenous Paclitaxel for Patients With Metastatic Breast Cancer
Patients with metastatic breast cancer who received an oral formulation of paclitaxel had better response and survival and less neuropathy than patients who received intravenous paclitaxel, according to results of a phase III trial presented at by Umanzor et al at the San Antonio Breast Cancer...
Thermal Ablation vs Cryotherapy or Loop Excision in Zambian Women Positive for Cervical Precancer
In the pilot phase of an ongoing randomized trial reported in The Lancet Oncology, Partha Basu, MD, and colleagues found that thermal ablation and cryotherapy produced similar treatment success rates in Zambian women positive for cervical precancer on visual inspection with acetic acid. The...
Studies Show the U.S. Health-Care System Hampered by Waste and Trailing Other High-Income Countries
Recent studies show that at least one-quarter of our nation’s health-care expenditures are being consumed by waste, fraud, and abuse. Moreover, since 2004, annual reports from the Commonwealth Fund have consistently rated the performance of our health-care system last among high-income countries,...
Making Inroads With Interventional Oncology in the Treatment of Solid Tumors
At the recent 2019 Symposium on Clinical Interventional Oncology (CIO) in Miami, course directors Constantino Peña, MD, FSIR, and Ripal Gandhi, MD, FSIR, FSVM, had a lot to say about this burgeoning field of oncology. In particular, interventional oncology is making inroads in therapeutic...
Expert Point of View: Angela Lamarca, MD, PhD, Ian Chau, MD, and Per Pfeiffer, MD, PhD
Angela Lamarca, MD, PhD, of the Christie NHS Foundation Trust, Manchester, United Kingdom, served as European Society for Medical Oncology (ESMO) commentator for the ClarIDHy trial in a press briefing held during the ESMO Congress 2019. Dr. Lamarca acknowledged, “The reported median...
Checkpoint Inhibitor Pneumonitis: A Pulmonologist’s Perspective
Oncologists have become accustomed to seeing pneumonitis associated with immune checkpoint inhibitor treatment in non–small cell lung cancer (NSCLC), requiring intervention by pulmonologists in the management of severe cases. At CHEST 2019, the annual meeting of the American College of Chest...
Emerging Alternatives in the Third-Line Setting for Metastatic HER2-Positive Breast Cancer
In the post-trastuzumab era, a number of U.S. Food and Drug Administration (FDA)-approved targeted agents for metastatic HER2-positive breast cancer are available, but there is no preferred option for third-line treatment and beyond. At the 2019 Chemotherapy Foundation Symposium, Shanu Modi, MD,...
Associations of Oncotype DX Breast Recurrence Score With Mortality Prediction and Difference Between Sexes
A study comparing the prognostic value of the Oncotype DX Breast Recurrence Score in male and female patients with early-stage estrogen receptor (ER)-positive breast cancer has found that the score is associated with mortality in male patients at a much lower threshold than female patients. The...
Thermal Ablation vs Cryotherapy or Loop Excision in Zambian Women Positive for Cervical Precancer
In the pilot phase of an ongoing randomized trial reported in The Lancet Oncology, Pinder et al found that thermal ablation and cryotherapy produced similar treatment success rates in Zambian women positive for cervical precancer on visual inspection with acetic acid. The investigators noted that...
Wake Forest Baptist Awarded $6 Million Grant to Study Web-Based Pain Management Program
For many people who have had cancer, severe pain can persist, even after treatment ends. In an effort to find a nonpharmaceutical approach to pain management for cancer survivors, researchers at Wake Forest Baptist Health have been awarded $6 million from the National Cancer Institute (NCI) to test ...
Oncology Clinicians Play A Role in Telling Patients About the Importance of Exercise
New exercise guidelines for patients with cancer can “improve physical and psychological outcomes from cancer diagnosis and for the balance of life,” concluded representatives from 17 organizations participating in the Second Roundtable on Exercise and Cancer Prevention and Control.1 Attention...
Despite Challenges, Pioneer in CT Screening for Early Lung Cancer Works to Move the Field Forward
In 1999, a team of researchers from Weill Cornell Medical College advocated the use of a then-novel practice: low-dose radiation CT screening for lung cancer. It captures a full thoracic image in a single breath hold, and can recognize a tumor in its earliest stages when the chance for cure is...
A Call to Action for Oncology Clinicians to Help Patients ‘Move Through Cancer’
“There is clear evidence that patients are more likely to exercise if their oncologist tells them to do so,” reported representatives from 17 organizations participating in the Second Roundtable on Exercise and Cancer Prevention and Control. In an article published in CA: A Cancer Journal for...
Analysis of 4-Year Survival With Nivolumab in Patients Previously Treated for Advanced NSCLC
In an analysis reported in The Lancet Oncology, Scott J. Antonia, MD, PhD, of Duke Cancer Institute, and colleagues identified long-term survival rates with nivolumab therapy in patients with previously treated advanced non–small cell lung cancer (NSCLC), including comparative outcomes vs...
Oncology Massage Therapy for Chemotherapy-Induced Peripheral Neuropathy
Oncology massage therapy might be a helping hand for patients suffering from chronic chemotherapy-induced peripheral neuropathy, according to data presented at the 2019 Supportive Care in Oncology Symposium.1 The results of the pilot study supported the premise that patients who received massages...
A Need for Human Connection Led to a Rewarding Career in Geriatric Oncology for Lodovico Balducci, MD
Older adults are the fastest-growing segment of our population, and more than 65% of patients with newly diagnosed cancer are 65 years of age or older. Although we now recognize the special needs of older patients with cancer, the field of geriatric oncology emerged quietly, with early growing...
An Oncologist’s Thoughtful Examination of Cancer and Personal Loss
“I could not have written this book when I was 30 years old. It is not because of any great discoveries I have made or research papers I have published since. It is because of the experience the intervening decades have given me as I cared for thousands of cancer patients and accompanied many to...
Study Finds Durvalumab Retreatment Active in Some Patients With Advanced Solid Tumors
Immunotherapy with checkpoint inhibitors offers a proportion of patients a chance at long-term disease control, resembling cure in some patients. Among the many questions about immunotherapy that remain to be resolved is whether patients who discontinue therapy and develop progressive disease can...
Physicians Should Lead by Example to Combat the Obesity Epidemic
American patients are suffering from an obesity crisis, where it is estimated that 300,000 deaths per year are due to obesity.1 The obesity trend is predicted to worsen, where it is projected that 85% of U.S. adults will be overweight or obese by 2030.2 Consequently, obesity-related illnesses are...
‘Clinically Meaningful’ Outcomes Seen in Two Studies of First-Line Immunotherapy for Hepatocellular Carcinoma
In the first-line treatment of advanced hepatocellular carcinoma, checkpoint inhibitors led to favorable outcomes in studies reported at the European Society for Medical Oncology (ESMO) Congress 2019—though one study was technically negative. The current first-line standard of care for unresectable ...
ASCO Updates Breast Cancer Risk Reduction Guideline to Include Anastrozole
ASCO has updated a guideline on pharmacologic interventions for breast cancer risk reduction in postmenopausal women at increased risk of developing breast cancer.1 The original clinical practice recommendations for breast cancer risk reduction were published in 1999 and updated in 2002, 2009, and...
Challenging the Global Community to Deliver Equitable Cancer Care for All
For Her Royal Highness Princess Dina Mired of Jordan, ensuring that every patient with cancer receives high-quality care is not an abstract goal—it is personal. Princess Dina saw firsthand the life-and-death differences that access to state-of-the-art oncology care makes in a patient’s life when...
Opioid Prescriptions in Patients With Cancer in Southwest Virginia
In a study in residents of rural southwest Virginia reported in the Journal of Oncology Practice, Virginia T. LeBaron, PhD, and colleagues found that most patients with cancer never received a prescription opioid medication, that few patients were admitted to hospital for opioid use disorders, and...
Improving Communication With Older Patients Using Geriatric Assessment During Oncology Visits
In the COACH study, reported in JAMA Oncology, Supriya G. Mohile, MD, MS, and colleagues found that including geriatric assessment in oncology visits for older adults with advanced cancer improved patient and caregiver satisfaction with communication regarding aging-related concerns. Study Details...
ESMO Congress 2019: Quick Takes From Key Clinical Trials
The ESMO Congress continues to grow as a pivotal platform for research in clinical oncology. At the ESMO Congress 2019, important findings were showcased in more than 2,200 studies, including 93 late-breaking abstracts. The ASCO Post summarized much of that news in separate articles over several...
Phase III PROfound Study Evaluates Olaparib in Setting of Metastatic, Castration-Resistant Prostate Cancer
Treatment with the poly (ADP-ribose) polymerase (PARP) inhibitor olaparib delayed disease progression and appears to improve survival, compared with newer hormonal agents in men with pretreated metastatic castration-resistant prostate cancer and homologous recombinant repair (HRR) genetic...
Short-Term Survival in Patients Aged 85 Years and Older After Colorectal Cancer Surgery
Results from a preliminary research study showed the majority of patients aged 85 years and older were still alive in the short-term after undergoing segmental colectomy for stage II and III colon cancer. Kaur et al presented these findings at the American College of Surgeons Clinical Congress...
Risk of Subsequent Malignant Neoplasms in Childhood Cancer Survivors After Treatment With Chemotherapy Alone
As reported in the Journal of Clinical Oncology by Turcotte et al, analysis of the Childhood Cancer Survivor Study Cohort showed that childhood cancer survivors treated with chemotherapy alone—particularly higher cumulative doses of platinum and alkylating agents—are at an increased risk of...
Head and Neck Melanoma in Adolescents and Young Adults: 1995 to 2014
Head and neck melanoma appears to be on the rise in young people in the United States and Canada, according to a study by Nosayaba Osazuwa-Peters, BDS, PhD, MPH, CHES, of the Saint Louis University (SLU) School of Medicine, and colleagues. Because the prognosis of head and neck melanoma is...
